Inpharma Weekly

, Volume 1017, Issue 1, pp 13–13 | Cite as

Insulin lispro heads advances in insulin therapy at EASD meeting

  • Robert Short
Newsletter Article


The human insulin analogue insulin lispro * dominated sessions on insulin preparations this year at the 31st Annual Meeting of the European Association for the Study of Diabetes [ Stockholm, Sweden; September 1995 ]. Of particular interest were the results of a 1037-patient study, which showed that the overall rate of hypoglycaemia in patients with insulin-dependent diabetes mellitus (IDDM) is significantly reduced during treatment with insulin lispro, compared with the rate seen during treatment with conventional insulin therapy. Insulin lispro is already approved for use in Russia and South Africa ** and plans are underway for its approval in several other countries.


Diabetes Mellitus Insulin Therapy Human Insulin European Association Analogue Insulin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1995

Authors and Affiliations

  • Robert Short

There are no affiliations available

Personalised recommendations